3 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
Aim of the study is to compare the efficacy and safety of the use of a low vacuum constant drainage system (Palin®) with a high vacuum closed suction drainage system (Medinorm S-400®) after chest wall masculinization in female-to-male transgenders.
Approved WMOCompleted
To demonstrate that Nanocort is safe and effectively reduces the inflammatory signs and symptoms of active GO.